| Literature DB >> 31102126 |
Jean Lucas G da Silva1,2, Daniela F Passos1,2, Viviane M Bernardes1,2, Fernanda L Cabral1,3, Paulo G Schimites1,3, Alessandra G Manzoni1,2, Edilene Gadelha de Oliveira4, Cristiane de Bona da Silva3, Ruy Carlos Ruver Beck4, Matheus H Jantsch1, Roberto M Maciel5, Daniela B R Leal6,7.
Abstract
We analyzed the effects of a nanoencapsulated association of curcumin and vitamin D3 on purine metabolism enzymes in neutrophils, lymphocytes, and platelets in a model of adjuvant-induced arthritis (AIA) in rats. Following AIA induction, the animals were treated for 15 days with free and nanoencapsulated curcumin (4 mg/kg), nanocapsules of vitamin D3 (VD3) (15.84 IU/day), a nanoencapsulated combination of curcumin and VD3, vehicle, or blank nanocapsules. The animals were euthanized, and blood was collected to evaluate the activities of E-NTPDase, adenosine deaminase (ADA), and myeloperoxidase (MPO), as well as reactive oxygen species (ROS) levels and biochemical parameters. Also, the liver and kidney were collected for histological analysis. The changes in the activities of purinergic enzymes indicated that inflammation was significantly reverted by vitamin D3 and curcumin co-nanoencapsulation treatments in the arthritic rats. The reduction of inflammation was confirmed by the reduction in the signs and symptoms of AIA, as well as in MPO activity by all formulations. The treatments with nanocapsules reverted histological alterations in the kidney. Serum parameters were not altered by the induction or treatments. Our results suggest that co-nanoencapsulation of vitamin D3 and curcumin is an efficient alternative adjuvant treatment for rheumatoid arthritis as it reverts the changes in the purine metabolism and reduces arthritis-associated inflammation.Entities:
Keywords: arthritis; curcumin; inflammation; purinergic system; vitamin D3
Mesh：
Substances：
Year: 2019 PMID： 31102126 DOI： 10.1007/s10753-019-01021-1
Source DB: PubMed Journal: Inflammation ISSN： 0360-3997 Impact factor: 4.092